Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

2(28.6%)

7Total

Phase 1(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01082653Phase 1Suspended

Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis

Role: lead

NCT01162915Phase 1Suspended

Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury

Role: lead

NCT00790764Phase 2Suspended

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

Role: lead

NCT00721006Phase 2Completed

Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

Role: lead

NCT00643981Phase 1Completed

Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia

Role: lead

NCT00518401Phase 1Completed

Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

Role: lead

NCT00548613Phase 1Completed

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

Role: lead

All 7 trials loaded